The Pharmacy Times® Diabetes Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of a group of chronic diseases that result in high blood glucose.
March 17th 2023
Finerenone is a first in class nonsteroidal mineralocorticoid receptor antagonist indicated in adults with chronic kidney disease associated with type 2 diabetes mellitus.
FDA Approves Integration of Abbott’s Updated Glucose Sensor With Automated Insulin Delivery System for Patients With DiabetesMarch 8th 2023
Newly modified FreeStyle Libre 2 and FreeStyle Libre 3 sensors can be worn by children aged 2 years and older with diabetes.
Newer Cardiovascular Drugs Are Being Incorporated Into Practice, but Access Remains a ChallengeMarch 6th 2023
Pharmacists play a vital role in ensuring that patients can afford their medications, either by advising them on more affordable options or working with insurers and prescribers to find cheaper alternatives.
Weight Problems Affect Americans With T1D Almost as Often as General PopulationFebruary 20th 2023
Findings highlight the need for evidence-based strategies to avoid being obese or overweight for patients with type 1 diabetes, which is often considered a disease of thin individuals.
Healthy Lifestyles May Lower Risk of Microvascular ComplicationsFebruary 10th 2023
Study results indicate that exercising, following a high-quality diet, limiting alcohol intake, maintaining a healthy body weight, and not smoking protects those with type 2 diabetes.
FDA to Review Application for Empagliflozin for Adults with Chronic Kidney DiseaseJanuary 26th 2023
In a phase 3 trial, empagliflozin significantly reduced the risk of kidney disease progression or cardiovascular death in adults with chronic kidney disease by 28% compared with placebo.
Study: Increased Coffee Consumption May Reduce Severity of Non-Alcoholic Fatty Liver Disease in Patients With Type 2 DiabetesJanuary 18th 2023
Individuals with higher caffeine levels were less likely to have liver fibrosis, while higher levels of non-caffeine coffee components were associated with reduced fatty liver index scores.